Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period
Küçük Resim Yok
Tarih
2014
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Kronik Lenfositik Lösemi (KLL), eriskinlerde en sık görülen lösemidir. KLL hastalarında, son zamanlarda CD38 ZAP70 ve hTERT etkinliğinin değerlendirilmesi ve prognozun yanında evreleme ve lenfosit ikileme zamanı ile iliskisinin belirlenebilmesi için çalısmalar yapılmaktadır. KLL hastalarında prognozun değerlendirilmesi için yapılan çalısmalarda tutarsız sonuçların olduğu görülmektedir. Bu çalısmada KLL hastalarında CD38 ZAP70 ve hTERT değerleri birbirleriyle ve bilinen prognostik faktörler arasında karsılastırma yapılarak değerlendirildi. Çalısmaya dâhil edilen 30 KLL hastası ilk tanıdan sonra 5 yıl boyunca takip edildi. KLL hastaları ve kontrol olguları ortalama hTERT değeri sırasıyla 1.00±1.31 ve 3.89±3.58 idi (p< 0.05). Ortalama CD38 ve ZAP70 değerleri sırasıyla 6.20±7.60 ve 5.51±5.67 olarak saptandı. CD38 ZAP70 ve hTERT aktiviteleri arasında anlamlı bir iliski saptanmadı. Bu parametrelerle, Rai evrelemesi, periferik lenfosit değerleri, yas, cinsiyet, beta-2 mikroglobulin (B2M) ve tedaviye cevap gibi bilinen prognostik faktörler arasında istatiksel olarak anlamlı bir fark saptanmadı. KLL hastalarında 5 yıllık ortalama sağ kalım süresi %96.7 olarak saptandı. Daha büyük, takip süreleri daha uzun hasta grupları ile ileri çalısmaların yapılmasının uygun olacağı düsünülmüstür.
Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in adults. Recently CD38, ZAP70 and hTERT activity have been studied for the evaluation of the prognosis of CLL besides clinical staging and lymphocyte doubling time. There are inconsistent results regarding these markers for the evaluation of the prognosis in CLL patients. In this study CD38, ZAP70 and hTERT values in CLL patients were measured to make comparisons between each other and known prognostic factors. Thirty CLL patients who were included in the study were followed up for 5 years after the initial diagnosis. The mean hTERT value in CLL and control cases were 1.00±1.31 and 3.89±3.58, respectively (p< 0.05). The mean CD38 and ZAP70 were 6.20±7.60 and 5.51±5.67, respectively. No significant association was detected between CD38, ZAP70 and hTERT activity. There was no correlation between those parameters and known prognostic parameters such as Rai staging, peripheral lymphocyte levels, age, and sex of the patients, beta-2 microglobulin and reply to treatment in CLL. The overall five-year survival rate in CLL patients is 96.7%. The overall five-year survival rate in CLL patients is 96.7%. In conclusion, further studies including larger series of patients with longer follow-up periods are recommended.
Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in adults. Recently CD38, ZAP70 and hTERT activity have been studied for the evaluation of the prognosis of CLL besides clinical staging and lymphocyte doubling time. There are inconsistent results regarding these markers for the evaluation of the prognosis in CLL patients. In this study CD38, ZAP70 and hTERT values in CLL patients were measured to make comparisons between each other and known prognostic factors. Thirty CLL patients who were included in the study were followed up for 5 years after the initial diagnosis. The mean hTERT value in CLL and control cases were 1.00±1.31 and 3.89±3.58, respectively (p< 0.05). The mean CD38 and ZAP70 were 6.20±7.60 and 5.51±5.67, respectively. No significant association was detected between CD38, ZAP70 and hTERT activity. There was no correlation between those parameters and known prognostic parameters such as Rai staging, peripheral lymphocyte levels, age, and sex of the patients, beta-2 microglobulin and reply to treatment in CLL. The overall five-year survival rate in CLL patients is 96.7%. The overall five-year survival rate in CLL patients is 96.7%. In conclusion, further studies including larger series of patients with longer follow-up periods are recommended.
Açıklama
Anahtar Kelimeler
Onkoloji
Kaynak
Uluslararası Hematoloji-Onkoloji Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
24
Sayı
3
